Reunion envisions a day when depression isn’t just managed, it’s curable. That’s why we relentlessly pursue the development of improved, safer, more accessible therapeutics. As an early-stage pharmaceutical company, we’re focused on neuroscience and developing new molecules for people with unmet needs.Learn More
RE104, our lead candidate, is a proprietary molecule which engages serotonergic receptors in the brain with the potential to induce therapeutically beneficial behavior changes in a variety of psychiatric conditions, including depression, in a manner similar to what has been demonstrated with psilocybin. Reunion's pipeline—the RE200 group—includes multiple discovery-phase candidates, which seek to improve upon the safety of serotonergic hallucinogens.
President & Chief Executive Officer
A leader in the pharmaceutical industry for over two decades, Greg brings a spectrum of successful experiences to Reunion from drug development to financings and acquisitions.
My goal as President and CEO of Reunion is to lead a company that will boldly disrupt the mental health sector with differentiated serotonergic psychedelic therapies.
Chief Financial Officer
Chief Science Officer
With three decades in nearly every aspect of pharmaceutical development, Dr. Bryson delivers proven experience and innovation to Reunion.
“Reunion is an opportunity for me to do what I’m passionate about: inspiring talent, growing teams, and building meaningful solutions for patients with unmet needs.”
General Counsel, Corporate Secretary
Vice President, Medical Affairs
Reunion’s team consists of experienced leaders in every aspect of pharmaceutical development. We’re dedicated to trailblazing the path to next-generation therapeutics to create a world where mental and emotional wellbeing are the baseline.Meet Reunion